Liminatus Pharma Inc-cl A-28 (LIMNW) Institutional Holdings & 13F Data (Q2 2026)

LIMNW ranks #8080 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

23 institutions disclose a position in LIMNW, but none treat it as a major bet — even Dupont Capital Management CORP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Dupont Capital Management CORP has added to its LIMNW position for two straight quarters, increasing it by $317.8K to reach $318.0K today.

Wolverine Asset Management LLC has trimmed its LIMNW position for two straight quarters, cutting it by $1.2K while still holding $1.0K.

LIMNW reported a net loss of $10.2M in its latest fiscal year.

• Not yet profitable — net loss of $10.2M in the latest fiscal year
• Net income declined year over year, from -$3.5M to -$10.2M
• Operating cash flow was negative, using $10.0M in cash
• Current ratio of 0.05x — below the conventional 1.5x liquidity buffer